Thyrocare Technologies Ltd

Thyrocare Tech. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Thyrocare Technologies Ltd

₹ 1,300 -2.85%
25 Jul 9:49 a.m.
thyrocare.com BSE: 539871 NSE: THYROCARE
About

Thyrocare Technologies is engaged in the business of healthcare industry and is involved in providing quality diagnostic services at affordable costs to patients, laboratories and hospitals in India.

Key Points

Business Segments
1) Diagnostic Testing Services (92% in FY25 vs 94% in FY22): [1] [2] The company is one of the leading Pan-India diagnostic chains, offering a range of tests focused on early disease detection and health management. It provides 929 tests and 288 profiles, including 43 wellness packages under the “Aarogyam” brand. It processes 3 Bn investigations annually and can process 10 Bn annually. [3] [4]

Website BSE NSE
  • Market Cap ₹ 6,890 Cr.
  • Current Price ₹ 1,300
  • High / Low ₹ 1,358 / 658
  • Stock P/E 65.5
  • Book Value ₹ 103
  • Dividend Yield 1.60 %
  • ROCE 24.8 %
  • ROE 16.0 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 135%
  • Company's working capital requirements have reduced from 24.3 days to 16.9 days

Cons

  • Stock is trading at 13.0 times its book value
  • The company has delivered a poor sales growth of 9.62% over past five years.
  • Company has a low return on equity of 13.8% over last 3 years.
  • Promoters have pledged or encumbered 100% of their holding.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Healthcare Services Healthcare Service Provider

Part of BSE Healthcare BSE SmallCap BSE Allcap

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
128 135 128 136 135 148 135 154 157 177 166 187 193
92 103 100 111 100 110 103 121 115 129 124 130 135
Operating Profit 36 32 28 25 35 38 32 34 42 48 42 57 58
OPM % 28% 23% 22% 18% 26% 25% 23% 22% 27% 27% 25% 30% 30%
1 2 3 4 1 3 3 3 4 3 4 5 5
Interest 1 1 1 1 1 1 1 1 1 1 1 1 1
Depreciation 9 9 10 11 10 11 13 13 11 13 17 14 11
Profit before tax 28 24 20 17 25 28 20 23 34 37 28 47 50
Tax % 22% 35% 25% 28% 31% 28% 26% 25% 29% 28% 32% 54% 24%
22 15 15 12 17 20 15 17 24 26 19 22 38
EPS in Rs 4.11 2.92 2.78 2.38 3.27 3.84 2.90 3.36 4.56 5.04 3.61 4.09 7.35
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
183 241 304 356 403 434 495 589 527 572 687 723
110 147 189 212 249 261 323 353 403 432 498 519
Operating Profit 73 94 115 145 154 174 171 236 123 140 190 204
OPM % 40% 39% 38% 41% 38% 40% 35% 40% 23% 24% 28% 28%
8 7 -15 21 11 1 12 29 9 9 15 16
Interest 0 1 0 0 1 2 1 3 5 6 4 3
Depreciation 13 18 18 20 26 32 30 34 39 47 55 55
Profit before tax 68 82 82 145 138 140 152 228 89 96 145 162
Tax % 35% 37% 48% 36% 38% 37% 26% 23% 27% 28% 38%
44 52 43 93 85 88 113 176 64 69 91 105
EPS in Rs 8.95 9.64 7.98 17.36 16.13 16.73 21.40 33.29 12.18 13.36 17.27 20.09
Dividend Payout % 171% 104% 125% 58% 124% 30% 117% 45% 148% 135% 122%
Compounded Sales Growth
10 Years: 14%
5 Years: 10%
3 Years: 5%
TTM: 22%
Compounded Profit Growth
10 Years: 7%
5 Years: -1%
3 Years: -18%
TTM: 38%
Stock Price CAGR
10 Years: %
5 Years: 17%
3 Years: 29%
1 Year: 73%
Return on Equity
10 Years: 19%
5 Years: 20%
3 Years: 14%
Last Year: 16%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 51 54 54 54 53 53 53 53 53 53 53
Reserves 226 312 354 390 382 314 374 474 481 474 494
-0 -0 -0 -0 2 12 8 21 23 42 25
53 44 30 36 37 90 106 60 74 75 121
Total Liabilities 329 410 438 479 475 469 541 607 632 644 693
196 259 259 299 294 269 253 285 294 306 297
CWIP 6 1 17 -0 1 5 8 3 2 3 14
Investments 86 93 104 120 95 90 126 146 144 162 162
42 56 58 60 84 105 154 173 192 173 220
Total Assets 329 410 438 479 475 469 541 607 632 644 693

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
34 68 90 107 100 168 115 113 129 168 191
-18 -18 -42 -43 -12 1 -49 -24 -39 -91 -53
-23 -45 -49 -64 -94 -165 -62 -89 -86 -85 -130
Net Cash Flow -6 5 -0 -0 -5 4 4 0 4 -8 8

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 10 11 8 10 11 14 33 58 59 28 39
Inventory Days 48 56 65 66 60 64 52 53 62 104 89
Days Payable 5 10 6 25 25 68 56 36 54 88 146
Cash Conversion Cycle 53 57 67 50 46 10 29 75 67 44 -18
Working Capital Days 28 2 19 10 28 -5 21 44 36 20 17
ROCE % 24% 28% 33% 30% 35% 36% 42% 17% 18% 25%

Shareholding Pattern

Numbers in percentages

Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025
71.14% 71.14% 71.14% 71.14% 71.14% 71.11% 71.11% 71.11% 71.11% 71.06% 71.06% 71.06%
10.42% 10.13% 9.99% 3.44% 3.46% 3.35% 2.90% 2.49% 1.93% 2.77% 2.41% 3.23%
9.14% 8.68% 8.45% 13.46% 13.33% 13.89% 14.88% 14.89% 14.79% 14.68% 14.97% 14.54%
9.29% 10.04% 10.40% 11.95% 12.08% 11.64% 11.11% 11.49% 12.15% 11.49% 11.57% 11.18%
No. of Shareholders 71,41275,82274,38676,29272,00068,84464,82361,63659,37756,66657,40354,566

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Concalls